📊 GNLX Key Takeaways
Is GNLX a Good Investment? Thesis Analysis
GENELUX is a development-stage pharmaceutical company with virtually no revenue ($8K) while burning $25.3M annually in operating cash, creating an unsustainable financial model. At current burn rates, the company's $5.3M cash position provides only 2-3 months of runway without additional financing or material revenue generation. The company faces immediate existential risk absent significant product commercialization or capital injection.
Genelux is effectively pre-revenue ($8k) with extremely negative margins and large operating losses (operating income -$33.21M, net income -$32.15M). While near-term liquidity appears adequate (current ratio 2.43x) and equity is positive, cash of $5.33M is insufficient versus a -$25.27M operating cash burn and $9.06M in long-term debt, indicating likely near-term financing needs. Until revenue traction or a material reduction in operating losses is demonstrated, fundamentals remain weak.
Why Buy GNLX? Key Strengths
- Positive stockholders' equity of $11.5M provides some accounting cushion
- Current ratio of 2.43x indicates adequate short-term liquidity relative to current liabilities
- Debt/equity ratio of 0.79x is moderate, not indicating extreme leverage
- Current ratio of 2.43x provides near-term liquidity
- Positive shareholders’ equity ($11.54M)
- Low capital intensity (capex $1.10M)
GNLX Investment Risks to Consider
- Cash burn of $25.3M annually against $5.3M cash reserves creates critical solvency timeline risk
- Revenue of only $8K indicates no meaningful commercial product sales or validation
- Massive operating losses of $33.2M with negative 415,175% operating margin signal fundamental business model failure
- Sustained heavy losses and cash burn (OCF -$25.27M)
- Minimal revenue base ($8k) offers no path to scale
- Leverage without coverage (no interest coverage; $9.06M long-term debt)
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway
- Revenue growth and pipeline product development stage transitions
- Capital raises and dilution events required to extend viability
- Operating cash flow (burn rate)
- Cash and equivalents (runway)
GNLX Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 2.43x current ratio provides a solid financial cushion.
GNLX Profitability Ratios
GNLX vs Healthcare Sector
How GENELUX Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is GNLX Overvalued or Undervalued?
Based on fundamental analysis, GENELUX Corp shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
GNLX Balance Sheet & Liquidity
GNLX 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: GENELUX Corp's revenue has declined by 100% over the 5-year period, indicating business contraction. The most recent EPS of $-0.95 indicates the company is currently unprofitable.
GNLX Growth Metrics (YoY)
GNLX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $8.0K | -$6.5M | $-0.19 |
| Q2 2025 | $8.0K | -$6.6M | $-0.20 |
| Q1 2025 | $8.0K | -$7.5M | $-0.21 |
| Q3 2024 | $8.0K | -$5.3M | $-0.19 |
| Q2 2024 | $8.0K | -$5.8M | $-0.22 |
| Q1 2024 | $8.0K | -$7.9M | $-0.29 |
| Q3 2023 | $170.0K | -$1.7M | $-0.19 |
| Q2 2023 | $170.0K | -$2.8M | $-0.23 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
GNLX Capital Allocation
GNLX SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for GENELUX Corp (CIK: 0001231457)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GNLX
What is the AI rating for GNLX?
GENELUX Corp (GNLX) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GNLX's key strengths?
Claude: Positive stockholders' equity of $11.5M provides some accounting cushion. Current ratio of 2.43x indicates adequate short-term liquidity relative to current liabilities. ChatGPT: Current ratio of 2.43x provides near-term liquidity. Positive shareholders’ equity ($11.54M).
What are the risks of investing in GNLX?
Claude: Cash burn of $25.3M annually against $5.3M cash reserves creates critical solvency timeline risk. Revenue of only $8K indicates no meaningful commercial product sales or validation. ChatGPT: Sustained heavy losses and cash burn (OCF -$25.27M). Minimal revenue base ($8k) offers no path to scale.
What is GNLX's revenue and growth?
GENELUX Corp reported revenue of $8.0K.
Does GNLX pay dividends?
GENELUX Corp does not currently pay dividends.
Where can I find GNLX SEC filings?
Official SEC filings for GENELUX Corp (CIK: 0001231457) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GNLX's EPS?
GENELUX Corp has a diluted EPS of $-0.86.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GNLX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, GENELUX Corp has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GNLX stock overvalued or undervalued?
Valuation metrics for GNLX: ROE of -278.5% (sector avg: 15%), net margin of -401,812.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy GNLX stock in 2026?
Our dual AI analysis gives GENELUX Corp a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GNLX's free cash flow?
GENELUX Corp's operating cash flow is $-25.3M, with capital expenditures of $1.1M. FCF margin is -329,575.0%.
How does GNLX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -401,812.5% (avg: 12%), ROE -278.5% (avg: 15%), current ratio 2.43 (avg: 2).